Beam Therapeutics Inc. BEAM

What this company does

The company has assembled a platform that includes gene editing and delivery technologies, as well as internal manufacturing capabilities. As of December 31, 2025, the company had 511 full-time team members, of whom 118 held an M.D. or Ph.D. degree, with 399 engaged in research and development and 112 in general and administrative roles. The company's lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. The company's base editors combine a CRISPR protein bound to a guide RNA, modified to avoid causing a double-stranded DNA break, with a base editing enzyme, such as a deaminase, that carries out the chemical modification of the target DNA base. The company has established a 100,000 square foot cGMP manufacturing facility in Research Triangle Park, North Carolina. In June 2017, the company entered into a license agreement with Harvard under which it received an exclusive, worldwide, royalty-bearing license to certain Harvard-owned patent rights covering base editing products for the prevention or treatment of human diseases and conditions.

Written from the business description in Beam Therapeutics Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 24 February 2026. Every sentence was checked against that document before publication.